Pharmaceutical Technology Europe, Sep 2, 2012 - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

Pharmaceutical Technology Europe, Sep 2, 2012
Collaborative Work can Lead to Innovation
By Dr Ralph Fink
In drug development, the majority of new chemical entities are lipophilic and/or poorly soluble. New actives often fail during development due to these challenging properties.
Open Alliance
A round table with Catalent and BASF on their new collaboration to provide bioavailability solutions.
Solid Dispersions by Hot-Melt Extrusion
By Andreas Gryczke
The advantages and disadvantages of hot-melt extrusion in solid dispersion formulations.
Rebranding Lipophilic Excipients
By Shaukat Ali , Nina Karpynec
Solubilizers play an important role in dissolving poorly soluble molecules. As the number of poorly soluble lipophilic and/or hydrophobic molecules increases—whether as "brick dusts" or waxy substances—the industry is struggling to identify the appropriate lipophilic excipients (surfactants, solubilizers, solvents or polymers) that can be used to develop such poorly soluble formulations into solid dosages and other forms of pharmaceutical products.
Bioavailability Enhancement
By Thomas Reintjes , Felicitas Guth
Soluplus®, a graft copolymer of PEG comprising polyvinyl acetate and polyvinyl caprolactam, was specially designed to solubilize poorly water-soluble drugs.
Lipid-Based Formulations
By Wei-Guo Dai
Development of viable dosage forms for poorly water-soluble compounds continues to be a significant challenge for formulation scientists, and insufficient bioavailability of such compounds may result in development delays or failures.
Spray Drying of Amorphous Dispersions
By Bend Research
Spray drying is a key process for manufacturing amorphous dispersions because of its breadth of applicability. The wide range of potential atomization techniques and controllable drying kinetics enables amorphous spray-dried dispersions (SDDs) to be produced from a wide variety of active pharmaceutical ingredients (APIs).
Addressing the Solubility Challenge
A Q&A with Karl Kolter, PhD, Head of Pharmaceutical Excipients R&D, BASF


LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Click here